NCT03345485: Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors |
|
|
| Completed | 1/2 | 71 | Canada, US | Tinostamustine (EDO-S101) | Mundipharma Research Limited | Small-cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer | 07/22 | 03/23 | | |
2020-004246-11: This study will evaluate the safety, tolerability and efficacy of Tinostamustine in late-stage cancer patients. Different types of solid tumors will be treated with Tinostamustine. The study will be performed in multiple centers and countries. |
|
|
| Not yet recruiting | 1/2 | 70 | Europe | Tinostamustine, EDO-S101, Lyophilisate for solution for infusion | Mundipharma Research Limited, MUNDIPHARMA RESEARCH LIMITED, Mundipharma Research Limited | • Cohort 1: Relapsed/refractory Small Cell Lung Cancer • Cohort 2: Relapsed/refractory Soft Tissue Sarcoma • Cohort 3: Relapsed/refractory Triple-Negative Breast Cancer • Cohort 4: Relapsed/refractory ovarian cancer • Cohort 5: Relapsed/refractory endometrial cancer On 05 March 2021 the Sponsor has taken the decision to halt recruitment into the Cohorts for relapsed/refractory triple-negative breast cancer (TNBC) and relapsed/refractory endometrial cancer on this study., "Relapse" means when a few of the original cancer cells survived the initial treatment. "Refractory" is a cancer that may be resistant at the beginning/becomes resistant during treatment., Diseases [C] - Cancer [C04] | | | | |
